logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10881729 B1

PDFFull Text
Date of Patent:
Jan. 05, 2021

Filed:

Apr. 17, 2015

Vaccine adjuvant compositions

Applicant:

Children's Medical Center Corporation, Boston, MA (US);

Inventors:

Simon D. Van Haren, Somerville, MA (US);

Ofer Levy, Cambridge, MA (US);

David J. Dowling, Brighton, MA (US);

Assignee:

CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US);

Attorneys:

Nixon Peabody LLP

David S. Resnick

Ravinderjit Braich

Primary Examiner:

Jana A Hines

Assistant Examiner:

Khatol S Shanhnan Shah

Int. Cl.
CPC ...
A21C 3/00 (2006.01); A61K 39/39 (2006.01); A61K 35/74 (2015.01); A61K 45/06 (2006.01); A61K 31/739 (2006.01); A61K 31/55 (2006.01); A61K 31/4745 (2006.01); A61K 31/716 (2006.01); A61K 31/7024 (2006.01); A61K 39/112 (2006.01); A61K 39/29 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 31/4745 (2013.01); A61K 31/55 (2013.01); A61K 31/7024 (2013.01); A61K 31/716 (2013.01); A61K 31/739 (2013.01); A61K 35/74 (2013.01); A61K 39/0275 (2013.01); A61K 39/29 (2013.01); A61K 45/06 (2013.01); C12N 7/00 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/57 (2013.01); C12N 2770/24234 (2013.01);
Abstract

Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave T cells to differentiate into IFN-γ-producing T cells, and for preventing and treating infections. The combinatorial composition comprises TLR and CLR agonists. The combinatorial composition comprises at least one TLR4 agonist and at least one Dectin-1 agonist, wherein the at least TLR4 agonist is monophosphoryl lipid A (MPLA) or glycopyranosyl lipid A (GLA), or the combinatorial composition comprises at least one TLR7/8 agonist and at least one Mincle agonist.

Find Patent Forward Citations

Loading…